Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs SAR 425899 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Acronyms MAD
- Sponsors Sanofi
- 26 Jun 2018 Results assessing the effects of SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with T2DM, presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 16 Sep 2016 Results of population PK/PD model using data from SAD and MAD studies presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 21 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.